Last update 20 Jun 2024
NM32-2668
Last update 20 Jun 2024
Overview
Basic Info
Drug Type Trispecific T-cell engager (TriTE) |
Synonyms NM32 2668, NM322668 |
Target |
Mechanism CD3 inhibitors(T cell surface glycoprotein CD3 inhibitors), ROR1 antagonists(Inactive tyrosine-protein kinase transmembrane receptor ROR1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Related
1
Clinical Trials associated with NM32-2668A Phase 1 Study of NM32-2668 (Anti-ROR1/CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients With Selected Advanced Solid Tumors
100 Clinical Results associated with NM32-2668
Login to view more data
100 Translational Medicine associated with NM32-2668
Login to view more data
100 Patents (Medical) associated with NM32-2668
Login to view more data
100 Deals associated with NM32-2668
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Adenocarcinoma of Lung | Phase 1 | US | 01 May 2024 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | US | 01 May 2024 | |
| Endometrial Carcinoma | Phase 1 | US | 01 May 2024 | |
| Fallopian Tube Carcinoma | Phase 1 | US | 01 May 2024 | |
| Gastroesophageal junction adenocarcinoma | Phase 1 | US | 01 May 2024 | |
| Leiomyosarcoma | Phase 1 | US | 01 May 2024 | |
| Liposarcoma | Phase 1 | US | 01 May 2024 | |
| Melanoma | Phase 1 | US | 01 May 2024 | |
| Mesothelioma, Malignant | Phase 1 | US | 01 May 2024 | |
| Ovarian Cancer | Phase 1 | US | 01 May 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free